{"id":45425,"date":"2025-10-31T15:54:36","date_gmt":"2025-10-31T07:54:36","guid":{"rendered":"https:\/\/flcube.com\/?p=45425"},"modified":"2025-10-31T15:54:36","modified_gmt":"2025-10-31T07:54:36","slug":"msd-reports-3-yoy-q3-2025-sales-growth-keytruda-drives-8-lift-verona-acquisition-strengthens-cardio%e2%80%91pulmonary-portfolio","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=45425","title":{"rendered":"MSD Reports 3% YoY Q3\u202f2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio\u2011Pulmonary Portfolio"},"content":{"rendered":"\n<p><strong>Merck, Sharp &amp; Dohme Inc.<\/strong> (MSD, <a href=\"https:\/\/www.google.com\/finance\/quote\/MRK:NYSE\">NYSE: MRK<\/a>) today announced its third\u2011quarter 2025 financial results, showing a 3\u202f% year\u2011over\u2011year (YoY) increase in constant\u2011exchange\u2011rate sales to <strong>$17.30\u202fbillion<\/strong>. The company\u2019s pharmaceutical segment grew 3\u202f% to <strong>$15.60\u202fbillion<\/strong>, led by oncology, cardiovascular, and diabetes products, while vaccines, virology, and immunology sales declined.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-highlights\"><strong>Financial Highlights<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Total Sales<\/strong> \u2013 $17.30\u202fB (+3\u202f% YoY, constant\u2011rate)<\/li>\n\n\n\n<li><strong>Pharmaceutical Sales<\/strong> \u2013 $15.60\u202fB (+3\u202f% YoY)<\/li>\n\n\n\n<li><strong>Keytruda (pembrolizumab)<\/strong> \u2013 $8.10\u202fB (+8\u202f% YoY)<\/li>\n\n\n\n<li><strong>GARDASIL\/GARDASIL\u202f9<\/strong> \u2013 $1.70\u202fB (\u201125\u202f% YoY, driven by China)<\/li>\n\n\n\n<li><strong>Winrevair (sotatercept)<\/strong> \u2013 $360\u202fM (+141\u202f% YoY)<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-segment-performance\"><strong>Segment Performance<\/strong><\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Segment<\/th><th>Q3\u202f2025<\/th><th>YoY %<\/th><th>Notes<\/th><\/tr><\/thead><tbody><tr><td><strong>Oncology<\/strong><\/td><td>$7.50\u202fB<\/td><td>+4\u202f%<\/td><td>Keytruda sales up 8\u202f%<\/td><\/tr><tr><td><strong>Cardiovascular<\/strong><\/td><td>$3.20\u202fB<\/td><td>+5\u202f%<\/td><td><\/td><\/tr><tr><td><strong>Diabetes<\/strong><\/td><td>$2.80\u202fB<\/td><td>+3\u202f%<\/td><td><\/td><\/tr><tr><td><strong>Vaccines<\/strong><\/td><td>$1.20\u202fB<\/td><td>\u201110\u202f%<\/td><td>China\u2011driven decline<\/td><\/tr><tr><td><strong>Virology &amp; Immunology<\/strong><\/td><td>$0.90\u202fB<\/td><td>\u20117\u202f%<\/td><td><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-moves\"><strong>Strategic Moves<\/strong><\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Manufacturing &amp; R&amp;D Investment<\/strong> \u2013 Break\u2011ground on a $3\u202fB Center of Excellence for Pharmaceutical Manufacturing at its Elkton, Virginia site, reinforcing U.S. capacity.<\/li>\n\n\n\n<li><strong>Verona Pharma Acquisition<\/strong> \u2013 Closed October\u202f2025, adding <strong>Ohtuvayre (ensifentrine)<\/strong>, a first\u2011in\u2011class FDA\u2011approved COPD maintenance therapy, to Merck\u2019s cardio\u2011pulmonary portfolio.<\/li>\n\n\n\n<li><strong>Product Pipeline<\/strong> \u2013 Continued focus on metastatic oncology indications and pulmonary arterial hypertension with Winrevair, which drove 141\u202f% revenue growth in Q3.<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This release contains forward\u2011looking statements that involve risks and uncertainties. Actual results may differ materially.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/Merck-Co-Inc-Rahway-N-J-USA-Announces-Third-Quarter-2025-Financial-Results-2025.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Merck--Co--Inc--Rahway-N-J--USA-Announces-Third-Quarter-2025-Financial-Results-2025.\"><\/object><a id=\"wp-block-file--media-5b38c9e0-903f-4ec2-9f8d-f333c43b6500\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/Merck-Co-Inc-Rahway-N-J-USA-Announces-Third-Quarter-2025-Financial-Results-2025.pdf\">Merck&#8211;Co&#8211;Inc&#8211;Rahway-N-J&#8211;USA-Announces-Third-Quarter-2025-Financial-Results-2025<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/Merck-Co-Inc-Rahway-N-J-USA-Announces-Third-Quarter-2025-Financial-Results-2025.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-5b38c9e0-903f-4ec2-9f8d-f333c43b6500\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Merck, Sharp &amp; Dohme Inc. (MSD, NYSE: MRK) today announced its third\u2011quarter 2025 financial results,&#8230;<\/p>\n","protected":false},"author":1,"featured_media":45429,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[27,2675,176,903],"class_list":["post-45425","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-finanical-reports","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MSD Reports 3% YoY Q3\u202f2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio\u2011Pulmonary Portfolio - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck, Sharp &amp; Dohme Inc. (MSD, NYSE: MRK) today announced its third\u2011quarter 2025 financial results, showing a 3\u202f% year\u2011over\u2011year (YoY) increase in constant\u2011exchange\u2011rate sales to $17.30\u202fbillion. The company\u2019s pharmaceutical segment grew 3\u202f% to $15.60\u202fbillion, led by oncology, cardiovascular, and diabetes products, while vaccines, virology, and immunology sales declined.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=45425\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSD Reports 3% YoY Q3\u202f2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio\u2011Pulmonary Portfolio\" \/>\n<meta property=\"og:description\" content=\"Merck, Sharp &amp; Dohme Inc. (MSD, NYSE: MRK) today announced its third\u2011quarter 2025 financial results, showing a 3\u202f% year\u2011over\u2011year (YoY) increase in constant\u2011exchange\u2011rate sales to $17.30\u202fbillion. The company\u2019s pharmaceutical segment grew 3\u202f% to $15.60\u202fbillion, led by oncology, cardiovascular, and diabetes products, while vaccines, virology, and immunology sales declined.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=45425\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-10-31T07:54:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3111.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45425#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45425\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MSD Reports 3% YoY Q3\u202f2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio\u2011Pulmonary Portfolio\",\"datePublished\":\"2025-10-31T07:54:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45425\"},\"wordCount\":214,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45425#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3111.webp\",\"keywords\":[\"Finanical Reports\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45425#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45425\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=45425\",\"name\":\"MSD Reports 3% YoY Q3\u202f2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio\u2011Pulmonary Portfolio - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45425#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45425#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3111.webp\",\"datePublished\":\"2025-10-31T07:54:36+00:00\",\"description\":\"Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) today announced its third\u2011quarter 2025 financial results, showing a 3\u202f% year\u2011over\u2011year (YoY) increase in constant\u2011exchange\u2011rate sales to $17.30\u202fbillion. The company\u2019s pharmaceutical segment grew 3\u202f% to $15.60\u202fbillion, led by oncology, cardiovascular, and diabetes products, while vaccines, virology, and immunology sales declined.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45425#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=45425\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45425#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3111.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/10\\\/3111.webp\",\"width\":1080,\"height\":608,\"caption\":\"MSD Reports 3% YoY Q3\u202f2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio\u2011Pulmonary Portfolio\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=45425#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MSD Reports 3% YoY Q3\u202f2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio\u2011Pulmonary Portfolio\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MSD Reports 3% YoY Q3\u202f2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio\u2011Pulmonary Portfolio - Insight, China&#039;s Pharmaceutical Industry","description":"Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) today announced its third\u2011quarter 2025 financial results, showing a 3\u202f% year\u2011over\u2011year (YoY) increase in constant\u2011exchange\u2011rate sales to $17.30\u202fbillion. The company\u2019s pharmaceutical segment grew 3\u202f% to $15.60\u202fbillion, led by oncology, cardiovascular, and diabetes products, while vaccines, virology, and immunology sales declined.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=45425","og_locale":"en_US","og_type":"article","og_title":"MSD Reports 3% YoY Q3\u202f2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio\u2011Pulmonary Portfolio","og_description":"Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) today announced its third\u2011quarter 2025 financial results, showing a 3\u202f% year\u2011over\u2011year (YoY) increase in constant\u2011exchange\u2011rate sales to $17.30\u202fbillion. The company\u2019s pharmaceutical segment grew 3\u202f% to $15.60\u202fbillion, led by oncology, cardiovascular, and diabetes products, while vaccines, virology, and immunology sales declined.","og_url":"https:\/\/flcube.com\/?p=45425","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-10-31T07:54:36+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3111.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=45425#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=45425"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MSD Reports 3% YoY Q3\u202f2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio\u2011Pulmonary Portfolio","datePublished":"2025-10-31T07:54:36+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=45425"},"wordCount":214,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=45425#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3111.webp","keywords":["Finanical Reports","Merck Sharp &amp; Dohme","MSD","NYSE: MRK"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=45425#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=45425","url":"https:\/\/flcube.com\/?p=45425","name":"MSD Reports 3% YoY Q3\u202f2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio\u2011Pulmonary Portfolio - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=45425#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=45425#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3111.webp","datePublished":"2025-10-31T07:54:36+00:00","description":"Merck, Sharp & Dohme Inc. (MSD, NYSE: MRK) today announced its third\u2011quarter 2025 financial results, showing a 3\u202f% year\u2011over\u2011year (YoY) increase in constant\u2011exchange\u2011rate sales to $17.30\u202fbillion. The company\u2019s pharmaceutical segment grew 3\u202f% to $15.60\u202fbillion, led by oncology, cardiovascular, and diabetes products, while vaccines, virology, and immunology sales declined.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=45425#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=45425"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=45425#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3111.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3111.webp","width":1080,"height":608,"caption":"MSD Reports 3% YoY Q3\u202f2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio\u2011Pulmonary Portfolio"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=45425#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MSD Reports 3% YoY Q3\u202f2025 Sales Growth, Keytruda Drives 8% Lift, Verona Acquisition Strengthens Cardio\u2011Pulmonary Portfolio"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/10\/3111.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45425","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=45425"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45425\/revisions"}],"predecessor-version":[{"id":45430,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/45425\/revisions\/45430"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/45429"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=45425"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=45425"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=45425"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}